Blog

Aug 2, 2024, 01:47

Sergio Cifuentes Canaval: Neoadjuvant Chemo-Immuno for ER+ HER- breast cancer

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT Mexico, shared on LinkedIn about recent paper by Alejandro Ríos-Hoyo et al., titled “Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer” published on Journal of Clinical Oncology.

Authors: Alejandro Ríos-Hoyo, Erin Cobain, Laura A. Huppert, Peter D. Beitsch, Thomas A. Buchholz, Laura Esserman, Laura J. van ‘t Veer, Hope S. Rugo, Lajos Pusztai.

“Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
– Congratulations to Alejandro Ríos-Hoyo.”

Source: Sergio Cifuentes Canaval/LinkedIn

Alejandro Ríos-Hoyo Breast Cancer cancer Erin Cobain Estrogen Receptor–Positive Human Epidermal Growth Factor 2 Hope S. Rugo Journal of Clinical Oncology Lajos Pusztai Laura A. Huppert Laura Esserman Laura J. van ‘t Veer OncoDaily Oncology Peter D. Beitsch Sergio Cifuentes Canaval Thomas A. Buchholz

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage